

# NIH Public Access

**Author Manuscript**

*Curr Opin Nephrol Hypertens*. Author manuscript; available in PMC 2010 March 30.

#### Published in final edited form as:

*Curr Opin Nephrol Hypertens*. 2009 January ; 18(1): 28–32. doi:10.1097/MNH.0b013e32831a9e0b.

# **Dopamine and Angiotensin as Renal Counter Regulatory Systems Controlling Sodium Balance**

#### **John J. Gildea**

Dept. of Pathology, University of Virginia, Charlottesville VA

### **Abstract**

**Purpose of the review—**To review the recent evidence demonstrating how the renal dopaminergic and angiotensin systems control renal electrolyte balance through various receptor mediated pathways with counter regulatory interactions.

**Recent Finding—**Stimulation of the renal renin angiotensin system (RAS) results in increased sodium reabsorption, while the opposite is true for stimulation of the renal dopaminergic system. An underactive renal dopaminergic system has been associated with increased sodium reabsorption and hypertension. Recent findings indicate novel cell surface receptor mediated mechanisms by which these two renal endocrine systems directly counter-regulate each other. Each of the dopamine receptors ( $D_1R$  through  $D_5R$ ) have been implicated in dopamine mediated natriuresis, in addition to counter-regulating the angiotensin type 1 R  $(AT_1R)$ . Dopamine  $D_1$ -like  $(D_1R$  and  $D_5R)$  stimulation has also been found to induce an  $AT_2$  receptor  $(AT_2R)$  dependent natriuresis. Recently, it has also been discovered that reactive oxygen species (ROS) can play a role in inactivating the  $D_1$  receptor and activating the  $AT_1R$ .

**Summary—**Current therapeutic interventions for hypertension predominantly involve correction of an overactive renin angiotensin aldosterone system. Recent evidence suggests that stimulation of the renal dopaminergic system and possibly activation of  $AT_2$  receptors, as well as decreasing ROS, may provide additional therapeutic approaches.

#### **Keywords**

Dopamine Receptors; Angiotensin Receptors; Counter-regulation; ROS; hypertension

#### **Introduction**

The counter-regulation of the renal dopaminergic and RAS will be examined in this review from the perspective of receptor-receptor interactions. The first part of the review will highlight the recent studies examining how the dopaminergic system impacts the regulation of the  $AT_1R$ . The next part of the review will summarize recent evidence that the dopaminergic system up regulates and activates the angiotensin type 2 receptor  $(AT<sub>2</sub>R)$ . The third section will review the evidence that the dopaminergic system in part counter-regulates the RAS by decreasing the production of ROS.

## **Dopamine inhibition of the angiotensin type 1 receptor (AT1R)**

The kidney, which regulates sodium and water balance, is a central organ in the regulation of electrolyte levels and blood volume in the body. Guyton described the relationship between blood pressure and sodium excretion as the pressure natriuresis curve. Increases in blood pressure cause increased natriuresis in order to return the blood pressure to normal. However, impairments in the pressure natriuresis relationship cause a rightward shift in the curve necessitating increased blood pressure in order to restore blood volume to normal. The

biochemical mechanisms governing the pressure natriuresis are just beginning to be understood with the RAS and dopaminergic systems acting as counter regulatory pathways involved in this process. There are two principal pathways which are responsible for the regulation of blood pressure, namely the natriuretic intrarenal dopamine system and the anti-natriuretic RAS (1). In order to conserve sodium during times of low sodium intake, the RAS is up-regulated in order to produce angiotensin II (Ang II). Stimulation of the principal membrane bound cell surface receptor for Ang II, the  $AT_1R$ , leads to sodium reabsorption. In order to eliminate sodium during times of high sodium intake the local renal production of dopamine is increased leading to inhibition of sodium reabsorption. Hypertension, or an inappropriately high blood pressure, can result when the kidney is unable to eliminate sodium and thus retains excess water leading to increased blood volume.

The renal renin-angiotensin system is a hormone cascade with the peptide hormone Ang II acting as its major product. Ang II exerts its effects primarily through the stimulation of the angiotensin type 1 receptor  $(AT_1R)$  leading to sodium reabsorption by the proximal tubule of the kidney. The first paper clearly showing the inhibitory activity of dopamine on the Ang II dependent increase in renal brush border sodium uptake *in-vitro* was shown by Sheikh-Hammad et al.(2), who measured radioactive  $Na^{22}$  uptake in isolated renal proximal tubule brush border vesicles. Both the  $D_1$ -like and  $D_2$ -like receptor activities were necessary for full inactivation of an Ang II dependant increase in sodium uptake. Cheng et al. then determined that the dopaminergic effect was accompanied by a downregulation of the AT1R both *invivo* as well as in cultured cells suggesting that the effect was not dependent on an intact kidney (3). Zeng et al. further demonstrated that Ang II stimulation caused a decrease in the  $D_5R$  in proximal tubule cells from WKY and SHR (4). Ang II stimulation caused a decrease in expression of  $AT_1R$  in WKY cells yet caused an increase in  $AT_1R$  expression in SHR. The  $AT_1R$  and  $D_5R$  were also found to co-localize in cells with the SHR rats having a lower basal expression of D<sub>5</sub>R. The AT<sub>1</sub>R and D<sub>5</sub>R are thought to be counter-regulatory since AT<sub>1</sub>R knockout animals have increased expression of  $D_5R$ , and  $D_5R$  knock-out mice have an increased expression of  $AT_1R$ .

Gildea et al. recently showed which D1-like receptor was responsible for the downregulation of the  $AT_1R$  in human renal proximal tubule cells (5). Using antisense oligos specific to the  $D_1R$  or the  $D_5R$  in primary cultured human renal proximal tubule cells, they presented evidence that it was the D<sub>5</sub>R that was mediating the D1-like effect on  $AT_1R$ . These studies utilized renal proximal tubular cells in which the  $D_1R$  was uncoupled from adenylyl cyclase stimulation. The  $D_5R$  downregulation of the  $AT_1R$  was intact in adenylyl cyclase uncoupled cells further suggesting that this was a  $D_1R$  and possibly a cAMP independent effect. This paper also showed for the first time that c-src is activated by stimulation of D1-like receptors and that the downregulation of the  $AT_1R$  is mediated by a c-src and a proteasome dependent protein degradation mechanism. Similarly, Li et al. showed that the  $D_5R$  that caused the ubiquitination and proteasomal degradation of the  $AT_1R$ , using both in-vitro and in-vivo techniques (6). He suggested that that the elevated blood pressure (relative to controls) in  $D_5R$  knock-out mice was due to the over-expression of the  $AT_1R$ . Another important finding was that the elevated blood pressure in the D<sub>5</sub>R knock-out mice could be returned to baseline using an  $AT_1R$ inhibitor, losartan. They further showed that the  $D_5R$  and  $AT_1R$  physically interact at the cell surface by co-immunoprecipitation and that the  $AT_1R$  that is ubiquitinated and degraded by the proteasome is the n-glycosylated form of the  $AT_1R$ . How c-src is activated by the  $D_5R$  and what role it plays in the ubiquitination and degradation of the  $AT_1R$  is yet to be determined. The dopamine D4 receptor ( $D_4R$ ) knockout mice also have over-expression of renal AT<sub>1</sub>R and a differential response to an  $AT_1R$  inhibitor, losartan, with the D4 knockout mice displaying an extended decrease in blood pressure reduction with bolus infusion of the  $AT_1R$  antagonist (6). There may be direct antagonism between the dopamine and the renin angiotensin system since either the D<sub>1</sub>R, D<sub>3</sub>R, or D<sub>5</sub>R can physically interact with the AT<sub>1</sub>R (7–10).

# **Dopamine dependant up-regulation of the angiotensin type 2 receptor (AT2R)**

The stimulation of the AT<sub>2</sub>R antagonizes many of the effects of the AT<sub>1</sub>R (11). The AT<sub>1</sub>R and the  $AT<sub>2</sub>R$  can physically interact producing the antagonism between the two signaling pathways (12). The fact that the stimulation of the  $AT_1R$  increases Na/KATPase activity has been demonstrated numerous times, while the  $AT<sub>2</sub>R$  was shown to inhibit Na/KATPase in isolated rabbit renal proximal tubule cells  $(13,14)$ . AT<sub>2</sub>R stimulation was also shown to induce natriuresis in obese Zucker and steptozocin induced diabetic rats via a nitric oxide, soluble guanylyl cyclase and cGMP mechanism (15,16). In human renal proximal tubule cells, it was also shown that this same downstream pathway leads to cGMP export from the cell and inhibited sodium absorption (17). Gildea et al. found that in immortalized human renal proximal tubule cells, D1-like stimulation caused the  $AT_2R$  to translocate to the cell surface and opposed the ability of  $AT_1R$  to decrease the expression of caveolin 1, and this only occurred in cells isolated from normotensive patients  $(18)$ . Salomone et al. showed that D<sub>1</sub>-like stimulation caused AT2R to translocate to the brush border of the rat renal proximal tubule *invivo*. This paper also showed that pharmacologically blocking the  $AT_2R$  blocked the dopamine D1-like dependent natriuresis (19). Interstitial infusion of fenoldopam, a  $D_1$ -like specific agonist, caused a proximal tubule dependent natriuresis in salt loaded adult rats, and co-infusion of an  $AT_2R$  specific blocking compound, PD-123319 (20), blocked the effect, suggesting that the  $AT_2R$  is necessary for D1-like effects on natriuresis.

The production of Ang II is down-regulated in high salt conditions and intrarenal dopamine production is increased (1,21). The elimination of the Ang II peptide is by a proteolytic cascade with the conversion of Ang II to Ang III by aminopeptidase A (APA) and the conversion of Ang III to Ang IV by aminopeptidase N (APN), both of which are highly expressed in the brush border of the renal proximal tubule (11). Natriuresis in salt loaded rats was induced by renal interstitial infusion of an  $AT_1R$  inhibitor, losartan, and the natriuresis is fully blocked by the AT<sub>2</sub>R inhibitor PD-123319 (20). Ang III appears to be the preferred substrate for AT<sub>2</sub>R dependent natriuresis because the Ang III induced natriuresis is blocked by the  $AT<sub>2</sub>R$  inhibitor PD-123319, and is enhanced by blocking the conversion of Ang III to Ang IV by an APN inhibitor (22). In addition, natriuresis caused by infusion of renal interstitial Ang II is blocked if you inhibit the conversion of Ang II to Ang III with an APA inhibitor (23). Perhaps the D1 like receptor or some other effect of increased sodium load may increase the conversion of Ang II to Ang III mediated by APA, or may decrease the activity of APN, which would produce an increase in the level of Ang III. A recent study showed that increasing sodium intake in rats caused an upregulation of total kidney expression of  $AT<sub>2</sub>R$  (24). In cell fractionation experiments  $AT<sub>2</sub>R$  and APN shifted to higher density cell fractions interpreted as being inhibited by internalization. The underlying mechanisms behind how dopaminergic stimulation coupled with  $AT_1R$  inhibition and  $AT_2R$  stimulation results in natriuresis remains to be determined.

#### **The dopaminergic system as an antioxidant**

Excess Ang II production can lead to renal pathology mediated through the  $AT_1R$ , causing excess growth, inflammation, and fibrosis resulting in chronic hypoxia (25) and increased generation of reactive oxygen species (ROS) (26). Dopamine stimulates antioxidant activity (27) and can counter-regulate Ang II signaling. Both the dopamine  $D_2$  receptor ( $D_2R$ ) and the D<sub>5</sub>R knock-out mice have increased ROS production (28,29). Interestingly, stimulation of D5R transfected HEK cells decreased ROS generation and was found to be independent of cAMP and PKA (28). In the case of  $D_5R$  knock-out mice, there is over expression of the  $AT_1R$  (8). Even though losartan was shown to bring the elevated blood pressure in D<sub>5</sub>R knockout mice back to normal and apocynin was also shown to return the blood pressure back to

baseline, it has not been shown that adding losartan blocks ROS production in these mice. In  $D_2R$  knock-out mice, there is no report of over expression of  $AT_1R$ , but it was documented that there was an increase in aldosterone secretion, a known downstream target of Ang II (29). Consistent with the increase in aldosterone being  $AT_1R$  mediated, increased sodium intake reduced the increase in aldosterone secretion. The addition of spironolactone, an aldosterone antagonist, normalized blood pressure but did not reduce urinary 8-isoprostane secretion, a measure of renal ROS generation. The dopamine D3 receptor  $(D_3R)$  knock-out mice are also hypertensive, and have over-expression of the  $AT_1R$  (9). Interestingly, addition of the dopamine  $D_3R$  specific agonist, PD128907, decreased expression of  $AT_1R$  in renal proximal tubule cells from WKY but increased expression of  $AT_1R$  in SHR. The addition of PD128907 also increased D3R expression in proximal tubule cells isolated from WKY rats but not in proximal tubule cells isolated from SHR, implying not just lack of signaling but differential signaling of the D<sub>3</sub>R in SHR. The D<sub>3</sub>R and  $AT_1R$  were also found for the first time to co-localize and co-immunoprecipitate from rat renal proximal tubule cells.

Some aspects of the dopaminergic system are not associated with an increase in ROS. G-protein coupled receptor kinase 4 (GRK4) is a kinase shown to phosphorylate and inactivate the  $D_1R$ (1). Over-expression of a genetic variant of GRK4- (A142V) in mice was shown not to increase ROS (30). The polymorphic version of the construct causes hypertension, presumably the result of hyperphosphorylation and inactivation of the  $D_1R$ , while the wild type version of the construct did not (31). The inactivation of the  $D_1R$ , at least in this instance, is not linked to the increased generation of ROS. While direct evidence that the  $D_1R$  specifically controls the antioxidant status of renal cells does not yet exist, it is known that an increase in ROS may inhibit  $D_1R$  (32,33). Addition of high salt diet alone did not cause a significant increase in blood pressure in Sprague-Dawley rats whereas the addition of an oxidant induced salt sensitivity (a sodium chloride mediated increase in blood pressure). The salt sensitive rats were further shown to have a defect in the  $D_1$ -like receptor dependent increase in fractional sodium excretion, cAMP production, and Na/KATPase activity, but showed no defect in dopamine production as measured by dopamine secreted into the urine.

In the obese Zucker rat model of ROS dependent hypertension, it was found that the  $D_1R$  was hyperphosphorylated by  $GRK<sub>2</sub>$  and was unable to inhibit Na/KATPase (34). It was further shown that this defect is due to an inability to activate phospholipase C (PLC). In this particular model of hypertension, the D1-like receptor dependent inhibition of Na/KATPase is insensitive to inhibition of PKA but is sensitive to PKC inhibitors. Interestingly, they showed that the defect in  $D_1R$  coupling to adenylyl cyclase in obese rats is reversed by dephosphorylating the  $D_1R$  in isolated membranes, yet does not restore PLC activation. There is an increase in the incidence of hypertension as well as an increase in the generation of ROS and inflammation with age. In a recent paper, it was shown that age related hypertension in rats may be reversed through the use of exercise which reduces several measures of ROS and inflammation in the kidneys from old rats, while at the same time increasing the abundance of  $D_1R$  (35). A paper by Banday et al. showed that increased oxidative activity (stimulated by L-buthionine sulfoximine) caused an increased  $AT_1R$  abundance in the renal proximal tubule and subsequent hypertension (36). The use of tempol (a novel cell permeable superoxide dismutase mimetic), reversed the oxidative stress induced increase in blood pressure. They further showed a heightened sensitivity to Ang II dependent increases in inositol triphosphate accumulation, PLC activation, MAP Kinase activation, Na/KATPase activity and NHE<sub>3</sub> activity.

#### **Summary**

The natriuretic renal dopaminergic system collectively opposes the anti-natriuretic activity of the RAS by both down-regulating the  $AT_1R$ , up-regulating the  $AT_2R$  and inhibiting ROS generation. Each of the individual dopamine receptors has been shown to oppose the activity

of the AT<sub>1</sub>R, with the D<sub>1</sub>R, D<sub>3</sub>R, and D<sub>5</sub>R physically interacting with the AT<sub>1</sub>R. The cell signaling pathways used by the individual members of the dopamine receptor family are complex and interconnected, yet work together to maintain normal blood pressure at least in part by inhibiting RAS activity and ROS production.

#### **References**

- 1. Felder RA, Jose PA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol 2006;2:637–650. [PubMed: 17066056]
- 2. Sheikh-Hamad D, Wang YP, Jo OD, Yanagawa N. Dopamine antagonizes the actions of angiotensin II in renal brush-border membrane. Am J Physiol 1993;264:F737–743. [PubMed: 8386474]
- 3. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 1996;97:2745–2752. [PubMed: 8675685]
- 4. Zeng C, Yang Z, Wang Z, Jones J, Wang X, Altea J, Mangrum AJ, Hopfer U, Sibley DR, Eisner GM, et al. Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells. Hypertension 2005;45:804–810. [PubMed: 15699451]
- 5\*\* . Gildea JJ, Wang X, Jose PA, Felder RA. Differential D1 and D5 receptor regulation and degradation of the angiotensin type 1 receptor. Hypertension 2008;51:360–366. This paper shows that the dopamine D5 receptor is the receptor responsible for the dopamine D1-like stimulated proteasomal and c-src dependent degradation of the  $AT_1R$  receptors. This paper also show that this pathway occurs in adenylyl cyclase uncoupled cells. [PubMed: 18172057]
- 6. Bek MJ, Wang X, Asico LD, Jones JE, Zheng S, Li X, Eisner GM, Grandy DK, Carey RM, Soaresda-Silva P, et al. Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptordeficient mice. Hypertension 2006;47:288–295. [PubMed: 16380537]
- 7. Zeng C, Wang Z, Hopfer U, Asico LD, Eisner GM, Felder RA, Jose PA. Rat strain effects of AT1 receptor activation on D1 dopamine receptors in immortalized renal proximal tubule cells. Hypertension 2005;46:799–805. [PubMed: 16172423]
- 8\*\* . Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, et al. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Invest. 2008 This paper conclusively demonstrates that the elevated blood pressure in D5 knockout mice is due to the AT1 receptor overexpression and that the cell surface n-glycosylated version of the AT1 receptor is ubiquitinated and sorted to the proteasome for degradation.
- 9. Zeng C, Liu Y, Wang Z, He D, Huang L, Yu P, Zheng S, Jones JE, Asico LD, Hopfer U, et al. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circulation Research 2006;99:494–500. [PubMed: 16902178]
- 10\* . Khan FSZ, Zelenin S, Holtbäck U, Scott L, Aperia A. Negative Reciprocity between Angiotensin II type 1 and Dopamine D1 receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol. 2008 Epub ahead of print. This paper shows that the Dopamine D1 receptor and AT1 receptor coimmunoprecipitate and that D1-like stimulation counter-regulates a well known effect of AT1 receptor, namely calcium signalling.
- 11. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends in Endocrinology & Metabolism 2008;19:84–87. [PubMed: 18294862]
- 12. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. Journal of Biological Chemistry 2001;276:39721–39726. [PubMed: 11507095]
- 13. Hakam AC, Hussain T. Angiotensin II type 2 receptor agonist directly inhibits proximal tubule sodium pump activity in obese but not in lean Zucker rats. Hypertension 2006;47:1117–1124. [PubMed: 16618840]
- 14. Hakam AC, Hussain T. Angiotensin II AT2 receptors inhibit proximal tubular Na+-K+-ATPase activity via a NO/cGMP-dependent pathway. American Journal of Physiology - Renal Physiology 2006;290:F1430–1436. [PubMed: 16380464]
- 15. Hakam AC, Siddiqui AH, Hussain T. Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats. American Journal of Physiology - Renal Physiology 2006;290:F503–508. [PubMed: 16204414]

- 16. Hakam AC, Hussain T. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 2005;45:270–275. [PubMed: 15596573]
- 17. Sasaki S, Siragy HM, Gildea JJ, Felder RA, Carey RM. Production and role of extracellular guanosine cyclic 3′, 5′ monophosphate in sodium uptake in human proximal tubule cells. Hypertension 2004;43:286–291. [PubMed: 14718358]
- 18. Gildea, J.; Yatabe, J.; Sasaki, M.; Wang, X.; Jose, P.; Felder, R. Up-regulation of the angiotensin type II receptor by dopamine-1 receptor stimulation in normotensive but not hypertensive human renal proximal tubule cells block angiotensin II dependent down-regulation of caveolin 1. Hypertension; Abstract for 59th Annual Fall Conference and Scientific Sessions of Council for High Blood Pressure Research; Washington, DC. September 2005; 2005.
- 19\*\* . Salomone LJ, Howell NL, McGrath HE, Kemp BA, Keller SR, Gildea JJ, Felder RA, Carey RM. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 2007;49:155–161. This paper showed for the first time that the  $AT<sub>2</sub>$  receptor is necessary for the D1-like increase in natriuresis in the kidney of rats on high sodium intake. Also showed D1-like stimulation of  $AT_2$  receptor translocation to the brush border of proximal tubules. [PubMed: 17116755]
- 20\* . Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 2006;47:537– 544. This paper showed that inhibiting APN activity in Ang III interstitial infusion in rats substantially increased natriuresis. [PubMed: 16380540]
- 21. Seri I, Kone BC, Gullans SR, Aperia A, Brenner BM, Ballermann BJ. Influence of Na+ intake on dopamine-induced inhibition of renal cortical Na(+)-K(+)-ATPase. American Journal of Physiology 1990;258:F52–60. [PubMed: 2154126]
- 22. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski MC, Roques BP, Carey RM. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 2007;49:625–630. [PubMed: 17190872]
- 23\*\* . Padia SH, Kemp BA, Howell NL, Fournie-Zaluski MC, Roques BP, Carey RM. Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension 2008;51:460–465. This paper shows that Ang III is the natriuretic peptide necessary for  $AT_2$  receptor dependent natriuresis by infusing Ang II and getting an increase in natriuresis, but if you block the conversion of Ang II to Ang III with an APA inhibitor you block natriuresis. [PubMed: 18158338]
- 24. Yang L, Sandberg M, Can A, Pihakashi-Maunsback K, McDonough A. Effects of dietary salt on renal Na+ transporters' subcellular distribution, abundance, and phosphorylation status. Am J Physiol Renal Physiol. 2008 [Epub ahead of print].
- 25. Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertension Research - Clinical & Experimental 2008;31:175–184.
- 26. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 2008;18:2439–2446. [PubMed: 17687073]
- 27\* . Han W, Li H, Villar VA, Pascua AM, Dajani MI, Wang X, Natarajan A, Quinn MT, Felder RA, Jose PA, et al. Lipid rafts keep NADPH oxidase in the inactive state in human renal proximal tubule cells. Hypertension 2008;51:481–487. This paper highlights the fact that the Dopamine receptors are found in lipid rafts in human proximal tubule cells, that Dopamine receptor stimulation reduces the production of reactive oxygen species, and disruption of lipid rafts increases ROS generation. [PubMed: 18195159]
- 28. Yang Z, Asico LD, Yu P, Wang Z, Jones JE, Escano CS, Wang X, Quinn MT, Sibley DR, Romero GG, et al. D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. American Journal of Physiology - Regulatory Integrative & Comparative Physiology 2006;290:R96–R104.
- 29. Armando I, Wang X, Villar VA, Jones JE, Asico LD, Escano C, Jose PA. Reactive oxygen speciesdependent hypertension in dopamine D2 receptor-deficient mice. Hypertension 2007;49:672–678. [PubMed: 17190875]
- 30\*. Wang Z, Armando I, Asico LD, Escano C, Wang X, Lu Q, Felder RA, Schnackenberg CG, Sibley DR, Eisner GM, et al. The elevated blood pressure of human GRK4gamma A142V transgenic mice

is not associated with increased ROS production. American Journal of Physiology - Heart & Circulatory Physiology 2007;292:H2083–2092. This paper shows that GRK4 inactivated dopamine type 1 receptor produces hypertension but does not lead to increases in reactive oxygen species. [PubMed: 17259440]

- 31. Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 2002;99:3872–3877. [PubMed: 11904438]
- 32\* . Banday AA, Fazili FR, Lokhandwala MF. Oxidative stress causes renal dopamine D1 receptor dysfunction and hypertension via mechanisms that involve nuclear factor-kappaB and protein kinase C. Journal of the American Society of Nephrology 2007;18:1446–1457. This paper shows that the  $D_1R$  can be inactivated by oxidative stress by a novel cell signalling pathway. [PubMed: 17409305]
- 33\*\* . Banday AA, Lau YS, Lokhandwala MF. Oxidative stress causes renal dopamine D1 receptor dysfunction and salt-sensitive hypertension in Sprague-Dawley rats. Hypertension 2008;51:367– 375. This paper shows that salt sensitivity can be caused by an increase in oxidative stress. [PubMed: 18158345]
- 34. Banday AA, Fazili FR, Marwaha A, Lokhandwala MF. Mitogen-activated protein kinase upregulation reduces renal D1 receptor affinity and G-protein coupling in obese rats. Kidney International 2007;71:397–406. [PubMed: 17191082]
- 35. Asghar M, George L, Lokhandwala MF. Exercise decreases oxidative stress and inflammation and restores renal dopamine D1 receptor function in old rats. American Journal of Physiology - Renal Physiology 2007;293:F914–919. [PubMed: 17634393]
- 36\* . Banday A, MFL. Oxidative stress induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension. Am J Physiol Renal Physiol. 2008 [Epub ahead of print] This paper shows that oxidative stress causes sensitization of the AT1 receptor.